Scarica l'app Stockscreener
26.41
2.08%
-0.56
Dopo l'orario di chiusura:
26.41
Precedente Chiudi:
$26.97
Aprire:
$26.86
Volume 24 ore:
539.80K
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.04B
Reddito:
$734.86M
Utile/perdita netta:
$5.14M
Rapporto P/E:
211.28
EPS:
0.125
Flusso di cassa netto:
$132.71M
1 W Prestazione:
+2.05%
1M Prestazione:
+4.10%
6M Prestazione:
+28.58%
1 anno Prestazione:
+25.23%
Intervallo 1D:
$25.97
$27.03
Intervallo di 1 settimana:
$25.77
$27.16
Portata 52W:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
26.41 | 1.04B | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira BioSciences Survey Finds Knee Pain Widespread Among Physically Demanding Workers, Driving Interest in Non-Opioid Treatment Options - Quiver Quantitative
Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pacira (PCRX) Advances Gene Therapy Manufacturing for Osteoarthritis - GuruFocus
Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone - marketscreener.com
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process - The Manila Times
Pacira's knee gene therapy gets new-process drug for Phase 2 - Stock Titan
Pacira Biosciences Inc (PCRX) Balance Sheet - TradingKey
Pacira Biosciences Inc (PCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacira Biosciences Inc (PCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pacira Biosciences Inc (PCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacira Biosciences, Inc. Revenue Breakdown – FWB:82P - TradingView
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pendi - The National Law Review
Pacira Biosciences Inc (PCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PCRX|Pacira Biosciences Inc|Price:26.470|Chg%:+0.590 - TradingKey
Pacira BioSciences, Inc. (PCRX) stock price, news, quote and history - Yahoo Finance Singapore
Pacira Pharmaceuticals, Inc. (PCRX) stock price, news, quote and history - Yahoo Finance UK
Pacira stock trades steady as EXPAREL revenue supports margins - Ad-hoc-news.de
Pacira BioSciences (PCRX) Climbs Nearly 2% as Stock Approaches Key Resistance LevelRSI Oversold Picks - dars.gov.et
Pacira Biosciences Inc (PCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacira stock trades steady as investors weigh Exparel growth and margin trends - Ad-hoc-news.de
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 - The Manila Times
Pacira will pair Aug. 4 results with a live investor Q&A - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring A Potential 17% Upside - DirectorsTalk Interviews
Understanding the Setup: (PCRX) and Scalable Risk - Stock Traders Daily
Pacira stock trades steady as investors weigh Q1 2026 revenue and margin trends - Ad-hoc-news.de
Pacira BioSciences stock trades steady as Exparel revenue supports valuation - Ad-hoc-news.de
PCRX6079820 Bond Coupon Profile — Rate & Payments - TradingView
PCRX6079820 Bond Profile — Key Metrics - TradingView
PCRX6079820 Bond Risk Profile - TradingView
Deals tracker: IKS Health acquires TruBridge in $557M deal - Modern Healthcare
Pacira BioSciences stock trades steady as pain-management pipeline stays in focus - AD HOC NEWS
82P Forecast — Price Target — Prediction for 2027 - TradingView
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira uses stock awards to recruit 10 new employees - Stock Titan
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Pacira to divest iovera business to Zimmer Biomet in up to $140M deal - MSN
UnitedHealthcare adds separate reimbursement for Exparel By Investing.com - Investing.com Australia
Sector Update: Healthcare - Moomoo
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL - markets.businessinsider.com
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings - marketscreener.com
PCRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® - The Manila Times
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.08%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):